AXGN Axogen Inc.

Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020

Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020
EN
08/10/2020

Underlying

AXGNAxogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axogen Inc.

 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Raymond James 47th Annual Institutional Investors ConferenceParticipation: Presentation and 1x1 investor meetingsDate/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ETWebcast Link:  Leerink Global Heal...

February 17, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Res...

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participa...

February 10, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Announces Pricing of Upsized $124 Million Public Offering of Co...

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition,...

January 22, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Announces Proposed Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common...

January 21, 2026 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter ...

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter o...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch